Back to School: How biopharma can reboot drug development. Access exclusive analysis here
sanofi-aventis (Euronext:SAN; SNY) said AVE5026 met the primary
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury